# Introduction

Roche Diagnostics Corporation hereby submits this Special 510(k) according to the requirements of 21 CFR 807.92. to provides sufficient detail to understand the basis for a determination of substantial equivalence for the Tina-quant HbA lc assay Gen 3.

# Submitter. name. address. contact

Roche Diagnostics 9115 Hague Road PO Box 50416 Indianapolis. IN 46250 Phone: 317-521-3831 Fax: 317-521-2324

Contact person: Kathie Goodwin

Date prepared: 9/31/2010

# Device name

Proprietary name: Tina-quant HbAlc Gen. 3

Common name: HbAlc Gen. 3

Classification name: Glycosylated Hemoglobin Assay

Product code: LCP

# Device description

With the Tina-Quant Hemoglobin Alc Gen. 3 test system. the anticoagulated whole blood specimen is hemolyzed prior to determination of HbA 1c by an turbidimetric inhibition immunoassay (TINIA). Liberated hemoglobin $\mathbf { ( H b ) }$ in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum and measured bichromatically. The instrument calculates the $\%$ HbA 1c from the HbA 1c/ Hb ratio according to a user selected protocol.

# Intended use

The Tina-Quant Hemoglobin A1c Gen. test is in vitro diagnostic reagent system intended for use on the COBAS INTEGRA 800 analyzers for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and $\%$ hemoglobin Alc ((DCCT/NGSP) in hemolysate or whole blood on Roche clinical chemistry analyzers. HbA 1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus.

# Predicate device

We claim substantial equivalence to the Tina-quant HbA1c Gen 2 assay cleared in K072714.

# 510(k) Summary - insert device name. Continued

Substantial equivalencesimilarities and differences   

<table><tr><td>Feature Intended Use</td><td>HbAlc Gen. 2 K072714 Whole blood application</td><td>HbAlc Gen. 3</td></tr><tr><td></td><td>In vitro test for the quantitative determination of percent hemoglobin Alc [HbA 1c (%)] in whole blood on Roche clinical chemistry analyzers Hemolysate Application: In vitro test for the Quantitative determination of percent hemoglobin Alc [HbA1c (%)] in hemolysate prepared from whole blood on Roche clinical chemistry analyzers</td><td>Whole blood application In vitro test for the quantitative determination of mmol/mol hemoglobin Alc (IFCC) and % hemoglobin Alc ( DCCT/NGSP) in whole blood on Roche clinical chemistry analyzers Hemolysate Application In vitro test for the quantitative determination of mmol/mol hemoglobin Alc (IFCC) and percent hemoglobin Alc ( DCCT/NGSP) in hemolysate prepared from</td></tr><tr><td></td><td></td><td>whole blood on Roche clinical chemistry analyzers.</td></tr><tr><td>Assay Protocol</td><td></td><td></td></tr></table>

The following table compares the HbA1c Gen 2 assay with the HbA1c Gen. 3 assay.

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">HbAlc Gen. 2K072714</td><td colspan="1" rowspan="1">HbAlc Gen. 3</td></tr><tr><td colspan="1" rowspan="1">Sample Types</td><td colspan="1" rowspan="1">Whole blood/Hemolysateapplications:Anticoagulated venous orcapillary blood with thefollowing anticoagulants:Li-heparinNa-heparinK2-EDTAK3-EDTApotassium fluoride/Na,-EDTASodium fluoride/Na-EDTASodium fluoride/potassium oxalate</td><td colspan="1" rowspan="1">Whole blood/Hemolysateapplications:Anticoagulated venous orcapillary blood with thefollowing anticoagulants:Li-heparinNa-heparinK2-EDTAK3-EDTApotassium fluoride/Na2-EDTASodium fluoride/Na-EDTASodium fluoride/potassium oxalate</td></tr><tr><td colspan="1" rowspan="1">Labeled InstrumentPlatform</td><td colspan="1" rowspan="1">Integra 400/400 plusIntegra 800</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Cfas HbA1c</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibration Frequency</td><td colspan="1" rowspan="1">Each lot. every 29 days. andas required following qualitycontrol procedures</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibration mode</td><td colspan="1" rowspan="1">Logit/log 5</td><td colspan="1" rowspan="1">Spline</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">HbA lc Control NHbAlc Control P</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">2-8 째C until expiration dateon-board in use @ 8째C 28days</td><td colspan="1" rowspan="1">SameIntegra 400/400plus:on board in use @ 10-15째C28 daysIntegra 800on-board in use @ 8째C: 28days</td></tr><tr><td>Feature Measuring Range</td><td>HbAic Gen. 2 K072714 Integra 400/400 plus</td><td>HbAlc Gen. 3 Integra 400/400 plus</td></tr><tr><td rowspan="2">Precision</td><td>Hb: 4 - 35 g/dL HbAlc: 0.3 - 2.6 g/dL* * Based on concentration of the highest standard</td><td colspan="2">Hb: 4 - 40 g/dL HbAlc:same</td></tr><tr><td>Integra 800 Hb: 4 - 35 g/dL HbA1c: 0.3 - 3.4 g/dL*</td><td colspan="2">Integra 800 Hb: 4 - 40 g/dL HbA1c: 0.3 - 2.6 g/dL</td></tr><tr><td colspan="2"></td><td colspan="3">Whole blood application</td></tr><tr><td rowspan="6"></td><td rowspan="6">Within-run: 0.8% @ 5.4 % HbA1c 0.9% @ 10.2 % HbA1c</td><td colspan="3">Repeatability:</td></tr><tr><td>sample</td><td>% CV</td><td>%HbA1c</td></tr><tr><td>HbA1c Control N</td><td>1.1</td><td>5.6</td></tr><tr><td>HbAIc Control P</td><td>0.8%</td><td>10.3</td></tr><tr><td>human sample 1</td><td>0.9%</td><td>4.7</td></tr><tr><td>human sample 2</td><td>0.8</td><td>5.8 8.7</td></tr><tr><td rowspan="4"></td><td>human sample 3:</td><td>0.7</td><td></td></tr><tr><td>human sample 4</td><td>1.5</td><td>12.4</td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="3"></td></tr></table>

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>HbAlc Gen. 2K072714</td><td rowspan=1 colspan=3>HbAlc Gen. 3</td><td></td></tr><tr><td rowspan=25 colspan=1>Precision, cont...</td><td rowspan=25 colspan=1>Whole blood application,cont...Between day1.3% @ 5.3 % HbAlc1.0% @ 10.3 % HbA1cHemolysate Application:Within-run:1.0% @ 5.5 % HbA1c0.6% @ 10.6 % HbA1cBetween day1.0 % @ 5.3 % HbAlc0.8% @ 10.7 % HbA1c</td><td rowspan=1 colspan=3>Whole blood application,cont...Intermediate precision:</td><td></td></tr><tr><td rowspan=1 colspan=1>sample</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>%HbA1C</td><td rowspan=2 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HbAIcControl N</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>HbA1cControl P</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 3:</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 4</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=4>Hemolysate ApplicationRepeatability:</td></tr><tr><td rowspan=1 colspan=1>sample</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%HbA1c</td><td></td></tr><tr><td rowspan=1 colspan=1>HbAIcControl N</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.6</td><td></td></tr><tr><td rowspan=1 colspan=1>HbAlcControl P</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>10.1</td><td></td></tr><tr><td rowspan=1 colspan=1>humansample 1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>humansample 2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 3:</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>humansample 4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=3>Intermediate precision:</td><td></td></tr><tr><td rowspan=1 colspan=1>sample</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%HbAIC</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HbAlcControl N</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HbAlcControl P</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>10.1</td><td></td></tr><tr><td rowspan=1 colspan=1>humansample 1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.7</td><td></td></tr><tr><td rowspan=1 colspan=1>humansample 2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>5.8</td><td></td></tr><tr><td rowspan=1 colspan=1>humansample 3:</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>8.7</td><td></td></tr><tr><td rowspan=1 colspan=1>humansample 4</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>12.0</td><td></td></tr><tr><td rowspan=1 colspan=3></td><td></td></tr></table>

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">HbAlc Gen. 2K072714</td><td colspan="1" rowspan="1">HbAlc Gen. 3</td></tr><tr><td colspan="1" rowspan="1">Analytical Sensitivity</td><td colspan="1" rowspan="1">LDLHb: 0.5 g/dLHbAlc: 0.1 g/dL '</td><td colspan="1" rowspan="1">LoBHb=0.50 g/dLHbA1c: 0.19 g/dLLoDHb=1.0 g/dLHbA1c: 0.29 g/dL</td></tr><tr><td colspan="1" rowspan="1">Analytical Specificity</td><td colspan="1" rowspan="1">Hb:Labile HbA1c (pre-HbAlc).acetylated Hb. carbamylatedHb do not affect the assayresultHb variants:Specimens containing highamounts of HbF(&gt; 10%)may yield lower thanexpected HbAlc results</td><td colspan="1" rowspan="1">samesame</td></tr><tr><td colspan="1" rowspan="1">EndogenousInterferences</td><td colspan="1" rowspan="1">Icterus: no significantinterferenceLipemia: no significantinterference up to atriglycerides conc of 600mg/dL ( Integra 400/400plus)and 800 mg/dL (Integra 800)Rheumatoid factors: nosignificant interference up to750 IU/mLGlycemia: no significantinterference up to 1000mg/dL</td><td colspan="1" rowspan="1">SameLipemia: no significantinterference up to aIntralipid conc of 800mg/dLsamesame</td></tr><tr><td colspan="1" rowspan="1">Expected Values</td><td colspan="1" rowspan="1">2.9 - 4.2 % HbA1c ( acc. toIFCC)4.8 -5.9 % HbA1c (acc. toDCCT/NGSP)</td><td colspan="1" rowspan="1">29 - 42 mmol/L HbA1c(acc. IFCC)same</td></tr><tr><td colspan="1" rowspan="1">Determination ofHbAlc</td><td colspan="1" rowspan="1">Turbidimetricimmunoinhibition (TINIA).Antigen-antibody complexesare formed and excess Abaggregate with polyhapten toform insoluble complexes</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Determination of Hb</td><td colspan="1" rowspan="1">Bichromatic photometricdetermination afterconversion to a coloredderivate</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Pretreatment</td><td colspan="1" rowspan="1">Whole blood applicationautomated on-board samplepretreatment withhemolyzing reagentHemolysate Application:Manual pretreatment withhemolyzing reagent</td><td colspan="1" rowspan="1">samesame</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Polyclonal anti-HbAlc fromsheep blood</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Reporting units</td><td colspan="1" rowspan="1">% HbA1c NGSP / DCCT</td><td colspan="1" rowspan="1">mmol/mol IFCC% HbA1c NGSP/DCCT</td></tr><tr><td colspan="1" rowspan="1">Equation used for finalHbAlc value</td><td colspan="1" rowspan="1">Protocol 1 ( acc. to IFCC)HbA1c(%)=(HbA1c/Hb)x100Protocol 2 ( acc. to DCCT/NGSP)HbA1c(%)=(HbA1c/Hb)x87.6+2.27</td><td colspan="1" rowspan="1">Protocol 1 ( acc. to IFCC)HbAIc(mmol/mol)=(HbA1c/Hb)x1000Protocol 2( acc. toDCCT/NGSP)HbA1c(%)=(HbA1c/Hb)x91.5+2.15</td></tr></table>

Roche Diagnostics Corporation c/o Ms. Kathie Goodwin 9115 Hague Road Indianapolis, Indiana 46250

JAN 2 0 2011

Re: k102914 Trade Name: Roche Tina Quant HbAlc Gen. 3 Assay Regulation Number: 21 CFR $\ S 8 6 4 . 7 4 7 0$ E Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Codes: LCP Dated: December 20, 2010 Received: December 21, 2010

Dear Ms. Goodwin:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21: CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/bfb39e6298d0333ff69751b60a51a401d320ea64180c2900264e254f69970e30.jpg)

Coukthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): K10914

Device Name: Tina-quant HbAlc Gen. 3

Indications for Use:

The Tina-Quant Hemoglobin Alc Gen. test is in vitro diagnostic reagent system intended for use on the COBAS INTEGRA 800 analyzers for the quantitative determination of mmol/mol hemoglobin Alc (IFCC) and $\%$ hemoglobin A1c (DCCT/NGSP) in hemolysate or whole blood on Roche clinical chemistry analyzers. HbA lc determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/89dcbef6dfc1460b115b8a4fa899e757cdea61a6043c50092793e1e0d052635e.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety